�Pathwork Diagnostics, Inc.,
a molecular diagnostics company focussed on oncology, announced that
the U.S. Food and Drug Administration (FDA) has cleared its Pathwork(R)
Tissue of Origin Test for use in determining the origin of uncertain
tumors. The test analyzes a tumor's factor expression approach pattern to assist
pinpoint the source of hard-to-identify tumors and is the low gear test of its
kind to receive FDA clearance. Up to an estimated 200,000 newly diagnosed
cancer patients annually in the U.S. may
